« Back

Zogenix Inc. filed an initial public offering Thursday with the Securities and Exchange Commission to sell up to $86.25 million of common stock.

The San Diego-based specialty pharmaceutical company has two product candidates in late-stage development for the treatment of central nervous system disorders and pain.

The company didn't disclose how many shares will be offered or an estimated price range in its prospectus filed with the SEC.

Zogenix said it expects to use the net proceeds from this offering to establish a sales and marketing infrastructure, to fund research and development activities and for working capital and other general corporate purposes.

The company hasn't generated any revenue since its inception in August 2006. It reported a net loss of $27.68 million for 2007.

Banc of America Securities LLC, Leerink Swann, Thomas Weisel Partners LLC and Susquehanna Financial Group are listed as underwriters for the IPO.

In January, Zogenix added $18 million in Series A funding led by new investor Abingworth Management, with participation from previous investors Clarus Ventures, Domain Associates, Scale Venture Partners and Thomas McNerney and Partners. Those previous investors, along with Life Science Angels, participated in a $60 million Series A round raised at its founding.

Domain owns 23.2% of Zogenix, Clarus owns 23.1%, Scale owns 15.4%, Thomas McNerney owns 13.2%, and Abingworth owns 10%, according to the SEC filing.

Zogenix has applied to list its common stock on the Nasdaq Global Market under the symbol ZGNX.

« Back